New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 116.4mg equivalent to ciprofloxacin 100 mg, as monohydrate - film coated tablet - 100 mg - active: ciprofloxacin hydrochloride 116.4mg equivalent to ciprofloxacin 100 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 291mg equivalent to ciprofloxacin 250 mg, as monohydrate - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291mg equivalent to ciprofloxacin 250 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 582mg equivalent to ciprofloxacin 500 mg, as monohydrate - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582mg equivalent to ciprofloxacin 500 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 873mg equivalent to ciprofloxacin 75 0mg, as monohydrate - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873mg equivalent to ciprofloxacin 75 0mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) - solution for infusion - 2 mg/ml - active: ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) excipient: hydrochloric acid lactic acid sodium chloride water for injection - infections of the lower respiratory tract. in the treatment of outpatients with pneumonia due to pneumococcus, ciprofloxacin should not be used as a medicine of first choice. ciprofloxacin can be regarded as a suitable treatment for pneumonias caused by klebsiella, enterobacter, proteus, e. coli, pseudomonas, haemophilus, branhamella, legionella, and staphylococcus.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ciprofloxacin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ciprofloxacin hydrochloride, quantity: 583 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; crospovidone; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 4000; titanium dioxide - ciprofloxacin is indicated for the treatment of infections caused by susceptible organisms in the following conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild to moderate severity. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pne

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ciprofloxacin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - hydrocortisone; ciprofloxacin -

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 10 g - oral suspension - 100 mg/ml - active: ciprofloxacin 10 g excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose